Form 4 for CRL Charles River Laboratories
Accepted 2023-05-31 00:00:00 ET · period of report 2023-05-26 · accession 0001127602-23-017133 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-31 | 2023-05-27+ | CRL | Girshick Birgit | COO, Corp. Executive VP | F - Tax | $194.12 | -590 | 43.8K | -1% | -$114.5K |
| D | 2023-05-31 | 2023-05-26 | CRL | Girshick Birgit | COO, Corp. Executive VP | A - Grant | $0.00 | +3,812 | 44.1K | +9% | $0 |
| D | 2023-05-31 | 2023-05-26 | CRL | Girshick Birgit | COO, Corp. Executive VP | A - Grant | $194.12 | +9,145 | 9,145 | New | +$1.78M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-29 | F | D | 216 | $194.12 | 43,477 | D | — | — | |
| 2 | Common | Common Stock | 2023-05-28 | F | D | 132 | $194.12 | 43,693 | D | — | — | |
| 3 | Common | Common Stock | 2023-05-27 | F | D | 242 | $194.12 | 43,825 | D | — | — | |
| 4 | Common | Common Stock | 2023-05-26 | A | A | 3,812 | $0.00 | 44,067 | D | — | — | (F1) Restricted Stock Units vest as follows: 953 on May 26, 2024, 953 on May 26, 2025, 953 on May 26, 2026 and 953 on May 26, 2027. |
| 5 | Derivative | Stock Options (Right to Buy) | 2023-05-26 | A | A | 9,145 | $194.12 | 9,145 | D | $194.12 · 2024-05-26 to 2033-05-26 | 9,145 Common Stock | (F2) Stock Options vest as follows: 2,286 on May 26, 2024, 2,286 on May 26, 2025, 2,286 on May 26, 2026 and 2,287 on May 26, 2027. |